The impact of sarcopenia on adverse events during neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Based on the results of JCOG1109, neoadjuvant DCF (docetaxel + cisplatin + 5-FU) therapy has become the standard strategy for advanced esophageal squamous cell carcinoma (ESCC) in Japan. While DCF therapy is expected to have a good response rate, it has a high incidence of adverse events, and its management is very important. Most ESCC patients are malnutrition at the time of initial diagnosis due to oral intake difficulties in addition to cancer cachexia. In this study, we investigated the relationship between adverse events (AE) and the skeletal muscle mass before chemotherapy.